<p>A) CHP-212 and SK-N-AS cells were treated with indicated concentrations of AZD6244, MEK162, Everolimus or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells were lysed and analysed by Western blot. Phosphorylation levels of AKT, ERK and S6 were detected by specific anti-phospho antibodies. Loading was verified by specific antibodies to total AKT, ERK and anti—tubulin. B) CHP-212 cells were treated with indicated concentrations of AZD6244, MEK162 or Everolimus or combinations thereof for 96h. Then, cell growth was measured by Cell Titer Glo. Combination index (CI) values with CalcuSyn Software (Biosoft). C) Same as B) but AZD8055 was used instead of Everolimus. D) SK-N-AS cells were treated with indicated concentrations ...
<p>(A) Western blot analysis of AKT, MEK, and ERK phosphorylation in the isogenic pair of NIH3T3 clo...
<p>(A) Combined mTOR and PLD1-/2-inhibitor treatment has a synergistic effect on blocking mTOR signa...
<p>(A) Control and AG–4 treated (5.4 μM, 0–48 h) cells were analyzed by western blot for phosphoryla...
<p>A-C) All indicated cell lines were kept under equal conditions. Cell lines were left untreated or...
<p>(<b>A</b>) The indicated cells were treated for 24 hrs. with rapamycin or BEZ235 and immunoblotte...
<p>A) CHP-212 and SK-N-AS cells were treated with 500nM of the MEK inhibitor MEK162 or the PI3K inhi...
<p>A) CHP-212 and SK-N-AS cells were treated with 5nM of the mTOR inhibitors Everolimus or 250nM AZD...
<p>Left hand panels: Growth inhibitory effects of combinations of trametinib with everolimus (TraEvl...
<div><p>BCR-ABL+ (PH and BV) and BCR-ABL- (HP) cells were treated with 0.5µM or 2µM NVP-BKM120 (PI3K...
BACKGROUND: Combined targeting of MAPK and PI3K signalling pathways may be necessary for optimal the...
<p>When MK-2206 was combined with the Mek1/2 inhibitor U0126, synergistic cytotoxicity was observed ...
<p>(A) PC9 and (B) PC9/AZDR cells were treated with various concentrations of AZD9291 alone, AZD6244...
BACKGROUND: ADPKD is a renal pathology caused by mutations of PKD1 and PKD2 genes, which encode for ...
<p>IC50 values (50% inhibition of growth) are shown for (A) trametinib, as well as (B) everolimus, N...
<p>(A) Phospho-flow on US7 cells using pErk1/2 (CST) or pMek (BD) antibodies in the left and right p...
<p>(A) Western blot analysis of AKT, MEK, and ERK phosphorylation in the isogenic pair of NIH3T3 clo...
<p>(A) Combined mTOR and PLD1-/2-inhibitor treatment has a synergistic effect on blocking mTOR signa...
<p>(A) Control and AG–4 treated (5.4 μM, 0–48 h) cells were analyzed by western blot for phosphoryla...
<p>A-C) All indicated cell lines were kept under equal conditions. Cell lines were left untreated or...
<p>(<b>A</b>) The indicated cells were treated for 24 hrs. with rapamycin or BEZ235 and immunoblotte...
<p>A) CHP-212 and SK-N-AS cells were treated with 500nM of the MEK inhibitor MEK162 or the PI3K inhi...
<p>A) CHP-212 and SK-N-AS cells were treated with 5nM of the mTOR inhibitors Everolimus or 250nM AZD...
<p>Left hand panels: Growth inhibitory effects of combinations of trametinib with everolimus (TraEvl...
<div><p>BCR-ABL+ (PH and BV) and BCR-ABL- (HP) cells were treated with 0.5µM or 2µM NVP-BKM120 (PI3K...
BACKGROUND: Combined targeting of MAPK and PI3K signalling pathways may be necessary for optimal the...
<p>When MK-2206 was combined with the Mek1/2 inhibitor U0126, synergistic cytotoxicity was observed ...
<p>(A) PC9 and (B) PC9/AZDR cells were treated with various concentrations of AZD9291 alone, AZD6244...
BACKGROUND: ADPKD is a renal pathology caused by mutations of PKD1 and PKD2 genes, which encode for ...
<p>IC50 values (50% inhibition of growth) are shown for (A) trametinib, as well as (B) everolimus, N...
<p>(A) Phospho-flow on US7 cells using pErk1/2 (CST) or pMek (BD) antibodies in the left and right p...
<p>(A) Western blot analysis of AKT, MEK, and ERK phosphorylation in the isogenic pair of NIH3T3 clo...
<p>(A) Combined mTOR and PLD1-/2-inhibitor treatment has a synergistic effect on blocking mTOR signa...
<p>(A) Control and AG–4 treated (5.4 μM, 0–48 h) cells were analyzed by western blot for phosphoryla...